CYTK / Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q2 2022 Results - Earnings Call Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice more_horizontal

Cytokinetics (CYTK) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of more_horizontal

Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest, Bloomberg News reported on Tuesday, citing p more_horizontal

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to repor more_horizontal

Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revi more_horizontal

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is schedule more_horizontal

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice P more_horizontal

Cytokinetics (CYTK) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of more_horizontal